Your browser doesn't support javascript.
Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking.
Shiakolas, Andrea R; Kramer, Kevin J; Johnson, Nicole V; Wall, Steven C; Suryadevara, Naveenchandra; Wrapp, Daniel; Periasamy, Sivakumar; Pilewski, Kelsey A; Raju, Nagarajan; Nargi, Rachel; Sutton, Rachel E; Walker, Lauren M; Setliff, Ian; Crowe, James E; Bukreyev, Alexander; Carnahan, Robert H; McLellan, Jason S; Georgiev, Ivelin S.
  • Shiakolas AR; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Kramer KJ; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Johnson NV; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Wall SC; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Suryadevara N; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Wrapp D; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Periasamy S; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Pilewski KA; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Raju N; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • Nargi R; Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
  • Sutton RE; Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
  • Walker LM; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Setliff I; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Crowe JE; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Bukreyev A; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Carnahan RH; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • McLellan JS; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Georgiev IS; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Nat Biotechnol ; 40(8): 1270-1275, 2022 08.
Article in English | MEDLINE | ID: covidwho-1730301
ABSTRACT
Although several monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been approved for coronavirus disease 2019 (COVID-19) therapy, development was generally inefficient, with lead generation often requiring the production and testing of numerous antibody candidates. Here, we report that the integration of target-ligand blocking with a previously described B cell receptor-sequencing approach (linking B cell receptor to antigen specificity through sequencing (LIBRA-seq)) enables the rapid and efficient identification of multiple neutralizing mAbs that prevent the binding of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). The combination of target-ligand blocking and high-throughput antibody sequencing promises to increase the throughput of programs aimed at discovering new neutralizing antibodies.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Nat Biotechnol Journal subject: Biotechnology Year: 2022 Document Type: Article Affiliation country: S41587-022-01232-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Nat Biotechnol Journal subject: Biotechnology Year: 2022 Document Type: Article Affiliation country: S41587-022-01232-2